CLAIM LISTING

1. (Currently Amended) A composition for delivering an agent ~~in~~ into a ~~target~~ neoplastic cell of a solid tumor expressing a neoplasm-specific antigen, comprising:

   (a) [a] an attenuated Salmonella or Shigella microorganism that has, on its [cell] surface, at least one ~~exogenous molecule~~ antibody or fragment thereof that binds to [an] a neoplasm-specific antigen on the surface of a ~~target~~ neoplastic cell of a solid tumor; and

   (b) an agent.

2.– 4. (Cancelled)

5. (Previously Presented) The composition of ~~claim 4~~ claim 1, wherein the Salmonella is Salmonella typhimurium VNP20009 or Salmonella typhimurium SL7207.

6. (Currently Amended) The composition of claim 1, wherein the ~~microorganism~~ Salmonella or Shigella expresses the ~~exogenous molecule~~ antibody or fragment thereof.

7. (Currently Amended) The composition of claim 6, wherein the ~~microorganism~~ Salmonella or Shigella transiently expresses the ~~exogenous molecule~~ antibody or fragment thereof.

8. – 10. (Cancelled)

11. (Previously Presented) The composition of ~~claim 10~~ claim 1, wherein the antibody is a mammalian antibody.

12. (Original) The composition of claim 11, wherein the antibody is a human antibody.

13. (Previously Presented) The composition of ~~claim 10~~ claim 1, wherein the antibody is a chimeric antibody.

14. (Original) The composition of claim 13, wherein the chimeric antibody is a humanized antibody.

15. (Previously Presented) The composition of ~~claim 10~~ claim 1, wherein the antibody is a single-chain antibody.

16. – 17 (Cancelled)

18. (Previously Presented) The composition of ~~claim 17~~ claim 1, wherein the solid-tumor [cell] is a colon-tumor [cell].

19. (Previously Presented) The composition of ~~claim 16~~ claim 1, wherein the neoplastic cell is a carcinoembryonic-antigen (CEA)-expressing cell.

20. (Previously Presented) The composition of ~~claim 19~~ claim 1, wherein the ~~CEA-expressing~~ neoplastic cell is selected from the group consisting of a bowel cancer cell, a breast cancer cell, a cervical cancer cell, a colon cancer cell, an esophageal cancer cell, a head cancer cell, a liver cancer cell, a lung cancer cell, a neck cancer cell, an ovarian cancer cell, a pancreatic cancer cell, and a stomach cancer cell.

21. (Previously Presented) The composition of ~~claim 20~~ claim 19, wherein the CEA-expressing cell is a colon cancer cell.

22. (Cancelled)

23. (Previously Presented) The composition of ~~claim 16~~ claim 1, wherein the antigen is selected from the group consisting of CAK1, CDK4, CDR2, carcinoembryonic antigen (CEA), disialoganglioside GD2, HER-2, large external antigen (LEA), MAGEs, MUC1, p21, podocalyxin, Ras, UK114, and WT1.

24. (Original) The composition of claim 23, wherein the antigen is a CEA.

25. (Original) The composition of claim 1, wherein the agent is selected from the group consisting of a diagnostic agent, a labeling agent, a preventive agent, and a therapeutic agent.

26. (Currently Amended) The composition of ~~claim 25~~ claim 1, wherein the ~~therapeutic~~ agent ~~is selected from the group consisting of~~ comprises ~~an anti-tumor compound, a lipid,~~ a

nucleic acid~~, a polypeptide, a polysaccharide, and a pro-drug or a pro-drug of an anti-tumor compound~~.

27. (Currently Amended) The composition of claim 26, wherein the nucleic acid ~~is a plasmid~~ comprises a plasmid encoding a polypeptide ~~selected from the group consisting of an anti-proliferation factor,~~ comprising an immuno-enhancing factor~~, a pro-apoptotic factor, and a pro-drug converting enzyme~~.

28. – 32. (Cancelled)

33. (Currently Amended) A method for treating a carcinoembryonic antigen (CEA)-expressing neoplasia in a subject in need of treatment, the method comprising:

a) administering to the subject a therapeutic composition in an amount effective to treat the neoplasia, wherein the therapeutic composition comprises:

i. [a] an attenuated Salmonella or Shigella microorganism that has, on its ~~cell~~ surface, at least one ~~exogenous molecule~~ antibody or fragment thereof that binds to [an] a neoplasm-specific antigen on the surface of a neoplastic cell of a solid tumor in the subject; and

ii. a therapeutic agent;

b) binding of the attenuated Salmonella or Shigella to the neoplastic cell; and

c) infecting the neoplastic cell.

34. (Cancelled)

35. (Currently Amended) The method of ~~claim 34~~ claim 33, wherein the solid tumor ~~is a colon tumor~~ selected from the group consisting of a breast tumor, a colon tumor, a lung tumor, a pancreatic tumor, and a stomach tumor.

36. (Previously Presented) The method of ~~claim 35~~ claim 33, wherein the solid tumor expresses carcinoembryonic antigen (CEA).

37. (Currently Amended) The method of ~~claim 36~~ claim 33, wherein the solid tumor is ~~selected from the group consisting of a bowel tumor, a breast tumor, a cervical tumor,~~ a colon tumor~~, an esophageal tumor, a head tumor, a liver tumor, a lung tumor, a neck tumor, an ovarian tumor, a pancreatic tumor, and a stomach tumor~~.

38. – 41. (Cancelled)

42. (Previously Presented) The method of ~~claim 41~~ claim 33, wherein the Salmonella is *Salmonella typhimurium* VNP20009 or *Salmonella typhimurium* SL7207.

43. (Currently Amended) The ~~composition~~ method of claim 33, wherein the ~~microorganism~~ Salmonella or Shigella expresses the ~~exogenous molecule~~ antibody or fragment thereof.

44. (Currently Amended) The ~~composition~~ method of claim 43, wherein the ~~microorganism~~ Salmonella or Shigella transiently expresses the ~~exogenous molecule~~ antibody or fragment thereof.

45. – 47. (Cancelled)

48. (Previously Presented) The method of ~~claim 47~~ claim 33, wherein the antibody is a mammalian antibody.

49. (Original) The method of claim 48, wherein the antibody is a human antibody.

50. (Previously Presented) The method of ~~claim 47~~ claim 33, wherein the antibody is a chimeric antibody.

51. (Original) The method of claim 50, wherein the chimeric antibody is a humanized antibody.

52. (Previously Presented) The method of ~~claim 47~~ claim 33, wherein the antibody is a single-chain antibody.

53. (Cancelled)

54. (Original) The method of claim 33, wherein the antigen is selected from the group consisting of CAK1, CDK4, CDR2, carcinoembryonic antigen (CEA), disialoganglioside GD2, HER-2, large external antigen (LEA), MAGEs, MUC1, p21, podocalyxin, Ras, UK114, and WT1.

55. (Original) The method of claim 54, wherein the antigen is a CEA.

56. (Currently Amended) The method of claim 33, wherein the therapeutic agent ~~is selected from the group consisting of~~ comprises ~~an anti-tumor compound, a lipid,~~ a nucleic acid~~, a polypeptide, a polysaccharide, and a pro-drug~~ or a pro-drug converting enzyme of an anti-tumor compound.

57. – 59. (Cancelled)

60. (Currently Amended) The ~~composition~~ method of ~~claim 57~~ claim 56, wherein the nucleic acid comprises a plasmid encoding a polypeptide comprising an immuno-enhancing factor ~~comprising at least one gene silencing cassette plasmid is an expression plasmid~~.

61. – 64. (Cancelled)

65. (Currently Amended) A method for treating a carcinoembryonic antigen (CEA)-expressing neoplasia in a subject in need of treatment, the method comprising:

a) administering to the subject a therapeutic composition in an amount effective to treat the neoplasia, wherein the therapeutic composition ~~consists of~~ comprises [a] an attenuated Salmonella or Shigella microorganism that has, on its ~~cell~~ surface, at least one ~~exogenous molecule~~ antibody or fragment thereof that binds to [an] a neoplasm- specific antigen on the surface of a neoplastic cell of a solid tumor in the subject;

b) binding of the attenuated Salmonella or Shigella to the neoplastic cell; and

c) infecting the neoplastic cell.

66. (New) The method of claim 33 or claim 65, wherein administering comprises dispersing the therapeutic composition to a subject via subcutaneous, intravenous, or oral delivery; or a combination thereof.